TEAM Atlassian Corporation - Fundamental Analysis

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and the absence of an Altman Z-Score limits distress risk assessment. Despite negative profitability metrics including a -3.38% profit margin and -15.35% ROE, the company demonstrates strong revenue growth of 20.60% and robust gross margins of 83.45%. Analysts maintain a 'buy' recommendation with a substantial upside implied by a $237.08 target price versus the current $118.55, though insider selling and deteriorating price performance over the past year raise caution. The stock trades at a premium valuation with a Price/Book of 22.64 and Forward P/E of 21.04, justified partially by growth but constrained by weak returns on capital.